Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | IGF2R | P11717 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
| ▸ | AMY2A | P04746 | 1/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22906104 | 0.89 | LGALS8 (0.37) | LGALS3LGALS8LGALS4KDM4EPOLB | |
| SCHEMBL22906178 | 0.89 | PYGB (0.40) | — | |
| SCHEMBL21391551 | 0.89 | PYGB (0.40) | — | |
| SCHEMBL21391520 | 0.89 | PYGB (0.40) | — | |
| SCHEMBL22906121 | 0.89 | PYGB (0.40) | — | |
| SCHEMBL10301424 | 0.85 | LGALS8 (0.53) | LGALS3LGALS8LGALS4KDM4EPOLB | |
| SCHEMBL12198736 | 0.85 | LGALS8 (0.53) | LGALS3LGALS8LGALS4KDM4EPOLB | |
| SCHEMBL21391539 | 0.83 | LGALS8 (0.48) | LGALS3LGALS8LGALS4KDM4EPOLB | |
| SCHEMBL21391509 | 0.83 | LGALS8 (0.48) | LGALS3LGALS8LGALS4KDM4EPOLB | |
| SCHEMBL22906135 | 0.83 | LGALS8 (0.48) | LGALS3LGALS8LGALS4KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| WO-2019182087-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OSTC, FUT6, FUT5 | LGALS3 188/4885LGALS8 253/4885LGALS4 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.